Do analysts rate ORMP or EXOZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ORMP or EXOZ more profitable?

Oramed Pharmaceuticals' return on equity of -5.37% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.37% -4.83% eXoZymes N/A -220.63% -141.26%

Does the media refer more to ORMP or EXOZ?

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than eXoZymes. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.85 beat Oramed Pharmaceuticals' score of 0.22 indicating that eXoZymes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate EXOZ or ARCT?

Arcturus Therapeutics has a consensus target price of $24.25, suggesting a potential upside of 243.97%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcturus Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Arcturus Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.64

Does the media refer more to EXOZ or ARCT?

In the previous week, Arcturus Therapeutics had 8 more articles in the media than eXoZymes. MarketBeat recorded 9 mentions for Arcturus Therapeutics and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.85 beat Arcturus Therapeutics' score of 0.46 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate EXOZ or CRBP?

Corbus Pharmaceuticals has a consensus price target of $41.13, suggesting a potential upside of 334.73%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Corbus Pharmaceuticals 2 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.60

Is EXOZ or CRBP more profitable?

Corbus Pharmaceuticals' return on equity of -87.05% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Corbus Pharmaceuticals N/A -87.05% -74.22%

Does the media prefer EXOZ or CRBP?

In the previous week, Corbus Pharmaceuticals had 16 more articles in the media than eXoZymes. MarketBeat recorded 17 mentions for Corbus Pharmaceuticals and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.85 beat Corbus Pharmaceuticals' score of -0.38 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corbus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate EXOZ or IPHA?

Innate Pharma has a consensus target price of $5.67, suggesting a potential upside of 155.26%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Innate Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, EXOZ or IPHA?

eXoZymes has higher earnings, but lower revenue than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eXoZymes $70K 684.17 -$9.16M -$1.14 N/A Innate Pharma $10.19M 20.46 -$55.64M N/A N/A

Is EXOZ or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Innate Pharma N/A N/A N/A

Does the media prefer EXOZ or IPHA?

In the previous week, Innate Pharma had 4 more articles in the media than eXoZymes. MarketBeat recorded 5 mentions for Innate Pharma and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.85 beat Innate Pharma's score of 0.00 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innate Pharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INDP or EXOZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is INDP or EXOZ more profitable?

eXoZymes' return on equity of -220.63% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -1,030.07% -299.69% eXoZymes N/A -220.63% -141.26%

Does the media favor INDP or EXOZ?

In the previous week, Indaptus Therapeutics and Indaptus Therapeutics both had 1 articles in the media. eXoZymes' average media sentiment score of 0.85 beat Indaptus Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

eXoZymes (EXOZ) Competitors

$5.20 +0.09 (+1.76%)

As of 03:57 PM Eastern

Compare

EXOZ vs. ORMP, ARCT, CRBP, IPHA, and INDP

Should you buy eXoZymes stock or one of its competitors? eXoZymes's main competitors and comparable companies include Oramed Pharmaceuticals (ORMP), Arcturus Therapeutics (ARCT), Corbus Pharmaceuticals (CRBP), Innate Pharma (IPHA), and Indaptus Therapeutics (INDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does eXoZymes compare to Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 72.4% of eXoZymes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Oramed Pharmaceuticals has higher revenue and earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	87.36	$64.05M	$2.59	1.62
eXoZymes	$70K	684.17	-$9.16M	-$1.14	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than eXoZymes. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.85 beat Oramed Pharmaceuticals' score of 0.22 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.93, suggesting that its stock price is 193% more volatile than the broader market.

Oramed Pharmaceuticals' return on equity of -5.37% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
eXoZymes	N/A	-220.63%	-141.26%

Summary

Oramed Pharmaceuticals beats eXoZymes on 8 of the 12 factors compared between the two stocks.

How does eXoZymes compare to Arcturus Therapeutics?

eXoZymes (NASDAQ:EXOZ) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

eXoZymes has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

94.5% of Arcturus Therapeutics shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Arcturus Therapeutics has a consensus target price of $24.25, suggesting a potential upside of 243.97%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcturus Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

eXoZymes has higher earnings, but lower revenue than Arcturus Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	684.17	-$9.16M	-$1.14	N/A
Arcturus Therapeutics	$82.03M	2.44	-$65.78M	-$3.31	N/A

In the previous week, Arcturus Therapeutics had 8 more articles in the media than eXoZymes. MarketBeat recorded 9 mentions for Arcturus Therapeutics and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.85 beat Arcturus Therapeutics' score of 0.46 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcturus Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

eXoZymes has a beta of 2.93, suggesting that its share price is 193% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market.

Summary

Arcturus Therapeutics beats eXoZymes on 9 of the 16 factors compared between the two stocks.

How does eXoZymes compare to Corbus Pharmaceuticals?

eXoZymes (NASDAQ:EXOZ) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

eXoZymes has higher revenue and earnings than Corbus Pharmaceuticals. eXoZymes is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	684.17	-$9.16M	-$1.14	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

In the previous week, Corbus Pharmaceuticals had 16 more articles in the media than eXoZymes. MarketBeat recorded 17 mentions for Corbus Pharmaceuticals and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.85 beat Corbus Pharmaceuticals' score of -0.38 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corbus Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Corbus Pharmaceuticals has a consensus price target of $41.13, suggesting a potential upside of 334.73%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Corbus Pharmaceuticals' return on equity of -87.05% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

eXoZymes has a beta of 2.93, suggesting that its stock price is 193% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.59, suggesting that its stock price is 159% more volatile than the broader market.

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats eXoZymes on 7 of the 13 factors compared between the two stocks.

How does eXoZymes compare to Innate Pharma?

eXoZymes (NASDAQ:EXOZ) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

eXoZymes has higher earnings, but lower revenue than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	684.17	-$9.16M	-$1.14	N/A
Innate Pharma	$10.19M	20.46	-$55.64M	N/A	N/A

Innate Pharma has a consensus target price of $5.67, suggesting a potential upside of 155.26%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

0.2% of Innate Pharma shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Innate Pharma had 4 more articles in the media than eXoZymes. MarketBeat recorded 5 mentions for Innate Pharma and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.85 beat Innate Pharma's score of 0.00 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innate Pharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

eXoZymes has a beta of 2.93, suggesting that its stock price is 193% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

Innate Pharma's return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Innate Pharma	N/A	N/A	N/A

Summary

Innate Pharma beats eXoZymes on 9 of the 14 factors compared between the two stocks.

How does eXoZymes compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

In the previous week, Indaptus Therapeutics and Indaptus Therapeutics both had 1 articles in the media. eXoZymes' average media sentiment score of 0.85 beat Indaptus Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.1% of Indaptus Therapeutics shares are held by institutional investors. 9.9% of Indaptus Therapeutics shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Indaptus Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.93, suggesting that its stock price is 193% more volatile than the broader market.

eXoZymes' return on equity of -220.63% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
eXoZymes	N/A	-220.63%	-141.26%

eXoZymes has higher revenue and earnings than Indaptus Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
eXoZymes	$70K	684.17	-$9.16M	-$1.14	N/A

Summary

eXoZymes beats Indaptus Therapeutics on 8 of the 9 factors compared between the two stocks.

Get eXoZymes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXOZ vs. The Competition

Export

Metric	eXoZymes	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$47.02M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	N/A	9.13	269.75	24.74
Price / Sales	684.17	1,274.20	652.34	108.60
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	13.00	17.66	11.27	6.42
Net Income	-$9.16M	-$13.25M	$3.45B	$347.12M
7 Day Performance	13.04%	5.36%	3.56%	2.48%
1 Month Performance	-25.39%	-1.74%	-0.58%	-1.04%
1 Year Performance	-47.15%	61.36%	77.52%	23.22%

eXoZymes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXOZ eXoZymes	0.522 of 5 stars	$5.20 +1.8%	N/A	-48.1%	$47.02M	$70K	N/A	29
ORMP Oramed Pharmaceuticals	2.7114 of 5 stars	$4.07 -1.2%	N/A	+105.7%	$168.62M	$2M	1.57	10	News Coverage Earnings Report
ARCT Arcturus Therapeutics	2.5393 of 5 stars	$5.76 -2.7%	$24.25 +321.0%	-37.8%	$168.26M	$42.35M	N/A	180	Earnings Report Analyst Upgrade
CRBP Corbus Pharmaceuticals	2.5376 of 5 stars	$8.97 -0.9%	$42.25 +371.0%	+20.6%	$167.68M	N/A	N/A	40	News Coverage Earnings Report Upcoming Earnings Analyst Forecast Insider Trade
IPHA Innate Pharma	2.3153 of 5 stars	$1.75 +0.3%	$5.00 +185.7%	-20.6%	$163.89M	$10.19M	N/A	220	News Coverage Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXOZ) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

eXoZymes (EXOZ) Competitors

EXOZ vs. ORMP, ARCT, CRBP, IPHA, and INDP

How does eXoZymes compare to Oramed Pharmaceuticals?

Summary

How does eXoZymes compare to Arcturus Therapeutics?

Summary

How does eXoZymes compare to Corbus Pharmaceuticals?

Summary

How does eXoZymes compare to Innate Pharma?

Summary

How does eXoZymes compare to Indaptus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

eXoZymes (EXOZ) Competitors

EXOZ vs. ORMP, ARCT, CRBP, IPHA, and INDP

How does eXoZymes compare to Oramed Pharmaceuticals?

Do insiders and institutionals have more ownership in ORMP or EXOZ?

Which has higher earnings and valuation, ORMP or EXOZ?

Do analysts rate ORMP or EXOZ?

Does the media refer more to ORMP or EXOZ?

Which has more volatility and risk, ORMP or EXOZ?

Is ORMP or EXOZ more profitable?

Summary

How does eXoZymes compare to Arcturus Therapeutics?

Is EXOZ or ARCT more profitable?

Do insiders & institutionals hold more shares of EXOZ or ARCT?

Do analysts rate EXOZ or ARCT?

Which has preferable valuation and earnings, EXOZ or ARCT?

Does the media refer more to EXOZ or ARCT?

Which has more risk & volatility, EXOZ or ARCT?

Summary

How does eXoZymes compare to Corbus Pharmaceuticals?

Which has better earnings & valuation, EXOZ or CRBP?

Does the media prefer EXOZ or CRBP?

Do analysts rate EXOZ or CRBP?

Is EXOZ or CRBP more profitable?

Which has more risk and volatility, EXOZ or CRBP?

Do institutionals and insiders hold more shares of EXOZ or CRBP?

Summary

How does eXoZymes compare to Innate Pharma?

Which has higher valuation & earnings, EXOZ or IPHA?

Do analysts rate EXOZ or IPHA?

Do institutionals & insiders hold more shares of EXOZ or IPHA?

Does the media prefer EXOZ or IPHA?

Which has more volatility and risk, EXOZ or IPHA?

Is EXOZ or IPHA more profitable?

Summary

How does eXoZymes compare to Indaptus Therapeutics?

Does the media favor INDP or EXOZ?

Do analysts prefer INDP or EXOZ?

Do insiders & institutionals hold more shares of INDP or EXOZ?

Which has more risk and volatility, INDP or EXOZ?

Is INDP or EXOZ more profitable?

Which has stronger earnings & valuation, INDP or EXOZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools